David Schlesinger leads product development and commercialization strategy at Acurion, where he is focused on bringing OncoGaze’s innovative HRD testing technology to patients who need it most. With over 12 years of product management experience in precision oncology and molecular diagnostics, he brings a proven track record of translating complex genomic science into commercially successful diagnostic products that improve patient outcomes.

Most recently at Natera, Dr. Schlesinger drove growth strategies for comprehensive genomic profiling in precision oncology, achieving 25% growth in test ordering volumes and creating training programs that enabled over 400 sales professionals to better serve oncologists and their patients. At SOPHiA GENETICS, he led the development and launch of the company’s Homologous Recombination Deficiency (HRD) Solution using deep learning, generating multi-million dollar revenues in its first year, the company’s most successful product launch.

Throughout his career at organizations including Exact Sciences, Illumina, and Thermo Fisher Scientific, Dr. Schlesinger has specialized in navigating complex regulatory pathways, building evidence-based reimbursement strategies, and executing international go-to-market plans. He is passionate about ensuring that precision oncology testing reaches all patients who can benefit from targeted therapies.

Dr. Schlesinger holds a PhD in Microbiology from the University of Illinois at Urbana-Champaign and has recently completed his Executive MBA from Quantic School of Business and Technology.